1	The potential causal association of systemic lupus erythematosus with
2	congestive heart failure in the East Asian population: A two-sample Mendelian
3	randomization study
4	
5	Euijun Song, M.D.
6	Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
7	
8	Correspondence: drjunsong@gmail.com (Euijun Song, M.D.)
9	
10	
11	Article type: Concise report (short article)
12	Conflict of interest: None.
13	

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

Abstract Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that increases the risk of cardiovascular disease, but the causal relationship has remained unknown in the East Asian population. We aim to determine the causal relationship between SLE and congestive heart failure (CHF) in the East Asian population. Methods: We conducted a two-sample Mendelian randomization (MR) study to examine the potential causal association of SLE with CHF, using the East Asian genome-wide association study datasets for SLE (4,222 cases, 8,431 controls) and CHF (9,413 cases, 203,040 controls). Results: The MR analysis showed that genetic susceptibility to SLE was associated with the increased risk of CHF (odds ratio [OR] 1.032, 95% confidence interval [CI] 1.004-1.061. P=0.023). After excluding the human leukocyte antigen (HLA) regions, SLE was also associated with a higher risk of CHF (OR 1.034, 95% CI 1.007-1.062, P=0.015). The multiple MR sensitivity analyses confirmed that this potential causal association was unlikely to be biased by horizontal pleiotropy. Conclusions: The findings of this MR study suggest that SLE potentially increases the risk of CHF in the East Asian population. Genetic predisposition to SLE may play a significant role in developing CHF in the East Asian population. Keywords: Systemic lupus erythematosus; Heart failure; Mendelian randomization; Genetic epidemiology; Cardio-rheumatology

What is already known on this topic

- Patients with systemic lupus erythematosus (SLE) have a higher risk of congestive heart failure (CHF) in the European and East Asian populations.

What this study adds

35

36

- The Mendelian randomization analysis suggests that genetic susceptibility to SLE was associated with a higher risk of CHF in the East Asian population.
- Non-human leukocyte antigen (HLA) variants associated with SLE were also associated with the increased risk of CHF.

How this study might affect research, practice, or policy

- Genetic predisposition to SLE may be useful to understand CHF risk stratification and management in the East Asian population.

1. Introduction

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can affect a variety of organs and systems in the human body, leading to rash, arthritis, lupus nephritis, anemia, and serositis. Patients with SLE have diverse autoantibodies against double-stranded DNA, cardiolipin, and ribonucleoproteins. Cardiovascular disease and infections are the leading causes of death in patients with SLE (1). Cardiovascular manifestation and complications of SLE include pericarditis, coronary artery disease, arrhythmias, valvular heart disease, and heart failure (2). Several retrospective cohort analyses and Mendelian randomization (MR) studies demonstrated that SLE increases the risk of coronary artery disease and heart failure, and worsens cardiovascular outcomes (3-6). However, most studies have been conducted in the European-dominant population, and the underlying mechanisms remain unclear. SLE and cardiovascular disease are complex diseases, and genetic predisposition plays an important role in both diseases (5). Here, we conduct a two-sample MR study to examine the potential causal association of SLE with congestive heart failure (CHF) in the East Asian population. We use large-scale summary-level genome-wide association study (GWAS) datasets for SLE and CHF in the East Asian population, and perform multiple MR methods to determine the potential causal effects of SLE on CHF. Since genetic variants within the human leukocyte antigen (HLA) region are not well understood and highly pleiotropic, we also performed our MR analysis after excluding the extended HLA region.

2. Methods

2.1. GWAS datasets for SLE and CHF

To perform the two-sample MR, we first recruited publicly available GWAS summary-level datasets for SLE and CHF in the East Asian population. For SLE, we used a Chinese GWAS summary-level dataset of 4,222 SLE cases and 8,431 controls from Wang et al (7). For CHF, we used the Biobank Japan GWAS summary statistics of 9,413 CHF cases and 203,040 controls (available from https://gwas.mrcieu.ac.uk/, dataset ID: bbj-a-109, accessed on Nov 6, 2022).

2.2. MR and statistical analysis

We constructed genetic instruments for SLE by extracting genome-wide significant variants (P<5x10⁻⁸) that were in low linkage disequilibrium (r^2 <0.001). The clumping was performed using the $clump_data$ function of the TwoSampleMR package based on the East Asian 1000 Genomes Project reference panel. We only considered non-palindromic variants in both SLE and CHF GWAS datasets. The instrument strength was evaluated using the F-statistic as $F = \left(\frac{n-k-1}{k}\right) \cdot \left(\frac{R^2}{1-R^2}\right)$, where n is the sample size, k is the number of the genetic variants, and R^2 is the proportion of variance explained by the genetic variants. The F-statistic greater than 10 indicates valid instruments. To evaluate the putative causal effect, we performed the inversevariance weighted (IVW), weighted median, maximum likelihood, MR-RAPS (8), MR-PRESSO (9), and radial MR (10) analyses. The heterogeneity between SNPs was evaluated by Cochran's Q test. The MR Steiger directionality test was also performed to determine the directionality of causality (11). To examine potential horizontal pleiotropy, we used the MR-Egger intercept test

(12) and MR-PRESSO method. We further performed the leave-one-out sensitivity analysis and radial MR to identify potential outlying variants. The P-value<0.05 was considered statistically significant. All MR analyses were performed with the TwoSampleMR, RadialMR, MR.RAPS, and MRPRESSO packages of R (version 4.1.2).

3. Results

3.1. The causal association of SLE with CHF

We used 30 genome-wide significant variants (P<5x10⁻⁸) as SLE-associated instrumental variables (Table S1). The genetic instruments for SLE have an F-statistic of 81.8, indicating no significant weak instrument bias in our MR analysis. We performed a two-sample MR analysis to examine the putative causal effects of SLE on CHF in the East Asian population. As highlighted in Table 1 (left column), the IVW method showed that SLE potentially increased the risk of CHF (odds ratio [OR] 1.032, 95% confidence interval [CI] 1.004–1.061, P=0.023). There was no evidence of heterogeneity (Cochran's Q-statistic=33.122, P=0.273). The weighted median, maximum likelihood, radial IVW, and MR-RAPS methods also showed directionally similar results (Table 1). Moreover, the MR Steiger directionality test confirmed the direction of the causality (P<0.001).

To examine potential horizontal pleiotropy, which could bias the MR analysis, we performed the MR-Egger intercept test and MR-PRESSO method. The MR-Egger intercept test showed no evidence of significant horizontal pleiotropy (intercept=0.01067, P=0.328). The MR-PRESSO

global test further indicated no significant pleiotropy with no outlying genetic variants (P=0.451). The removing individual variants did not substantially alter the estimated causal effect (Figure S1A). The radial MR method identified the outlying variants (rs143821594 and rs4930642); however, the excluding that outlier also led to the concordant MR result (OR 1.032, 95% CI 1.004–1.061, P=0.023; Figure S2A). Additionally, the MR-RAPS was used to test whether SLE affects CHF through weak instruments (OR 1.032, 95% CI 1.003–1.061, P=0.029). Multiple sensitivity analyses indicate no significant evidence for pleiotropic effects in our MR analysis.

3.2. Effects of non-HLA SLE-associated variants on CHF

Since GWAS loci within the HLA region are difficult to finely map and are highly pleiotropic to complex diseases, we repeated our MR analysis after excluding the extended HLA region (chromosome 6: 27–34 Mb). Three genetic variants (rs2524058, rs6941112, and rs143821594) were excluded. Using IVW, we found that SLE was causally associated with the risk of CHF (OR 1.034, 95% CI 1.007–1.062, P=0.015). The weighted median, maximum likelihood, radial IVW, and MR-RAPS methods showed directionally similar estimates (Table 1, right column). The MR-Egger intercept test (intercept=0.00930, P=0.385) and MR-PRESSO global test indicated no significant evidence of horizontal pleiotropy (P=0.689). The leave-one-out sensitivity analysis and the radial plot are presented in Figure S1B and Figure S2B, respectively. Furthermore, we also found that SLE was causally associated with CHF after excluding the entire chromosome 6 (OR 1.037, 95% CI 1.004–1.072, P=0.030; Table S2). The overall results are concordant with those acquired from the whole SLE-associated variants.

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

4. Discussion The causal relationship between SLE and CHF in the East Asian population has been largely unknown. In the present MR study, we discovered that SLE potentially increased the risk of CHF in the East Asian population. The non-HLA SLE-associated variants were also causally associated with CHF. The multiple MR sensitivity analyses confirmed that this potential causal association was unlikely to be biased by horizontal pleiotropy, indicating the robustness of effect estimates. In the US retrospective studies, SLE was associated with a 2.7-3.17-fold increase in the risk of CHF (3, 4). Recently, European-dominant MR studies also revealed that SLE potentially increases the risk of CHF, coronary artery disease, ischemic stroke, and venous thromboembolism (5, 6). A Korean nationwide study found that patients with SLE had a 4.6-fold higher risk of CHF (13). In our MR study, the effect size of SLE on CHF (OR 1.032, 95% CI 1.004-1.061) was relatively smaller compared to previous retrospective studies. Therefore, developing CHF in patients with SLE may be attributed to other environmental factors and SLE medications, such as hydroxychloroguine and steroid, as well as the genetic predisposition for SLE per se. Indeed, hydroxychloroquine and steroid, commonly used medications in SLE, increases the risk of diabetes mellitus, dyslipidemia, and cardiomyopathy (14, 15). These drug-induced risk factors for cardiovascular diseases may lead to bias in retrospective cohort studies. In contrast, we demonstrated that genetically predisposed SLE was associated with CHF in the East Asian

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

population using the MR analysis. Thus, MR approaches could identify potential causal associations without conducting prospective clinical trials. There are several limitations of this study. There is limited availability of large-scale SLE GWAS datasets, especially for the East Asian population, restricting statistical power underlying the polygenic pathobiology of SLE. In our analysis, the weighted median method did not show significant results; however, IVW is more statistically powerful than other MR methods. We also did not perform replication analysis in other East Asian datasets, though large-sale SLE GWAS datasets are not currently available. The linkage disequilibrium score regression and pathway/network analyses would uncover potential pathobiological connections between SLE and CHF. **Acknowledgements** This research received no external funding. In the present work, we only used publicly available GWAS summary statistics datasets. The author would like to thank Dr. Cheng for his kind support.

References

- 165 1. Moghaddam B, Marozoff S, Li L, Sayre EC, Zubieta JAA. All-cause and cause-specific mortality in
- systemic lupus erythematosus: a population-based study. Rheumatology. 2022;61(1):367-76.
- 167 2. Dhakal BP, Kim CH, Al-Kindi SG, Oliveira GH. Heart failure in systemic lupus erythematosus.
- 168 Trends Cardiovasc Med. 2018;28(3):187-97.
- 169 3. Kim CH, Al-Kindi SG, Jandali B, Askari AD, Zacharias M, Oliveira GH. Incidence and risk of heart
- failure in systemic lupus erythematosus. Heart. 2017;103(3):227-33.
- 171 4. Chen SK, Barbhaiya M, Fischer MA, Guan H, Yoshida K, Feldman CH, et al. Heart failure risk in
- 172 systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Semin
- 173 Arthritis Rheum. 2019;49(3):389-95.
- 174 5. Kain J, Owen KA, Marion MC, Langefeld CD, Grammer AC, Lipsky PE. Mendelian randomization
- and pathway analysis demonstrate shared genetic associations between lupus and coronary artery
- 176 disease. Cell Rep Med. 2022:100805.
- 177 6. Gao N, Kong M, Li X, Wei D, Zhu X, Hong Z, et al. Systemic Lupus Erythematosus and
- 178 Cardiovascular Disease: A Mendelian Randomization Study. Front Immunol. 2022;13:908831.
- 179 7. Wang YF, Zhang Y, Lin Z, Zhang H, Wang TY, Cao Y, et al. Identification of 38 novel loci for
- systemic lupus erythematosus and genetic heterogeneity between ancestral groups. Nat Commun.
- 181 2021:12(1):772.
- 182 8. Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summary-
- data Mendelian randomization using robust adjusted profile score. The Annals of Statistics.
- 184 2020;48(3):1742-69.
- 185 9. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal
- relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet.
- 187 2018;50(5):693-8.
- 188 10. Bowden J, Spiller W, Del Greco MF, Sheehan N, Thompson J, Minelli C, et al. Improving the
- 189 visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the
- 190 Radial plot and Radial regression. Int J Epidemiol. 2018;47(4):1264-78.
- 191 11. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely
- measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.
- 193 12. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-
- 194 Egger method. Eur J Epidemiol. 2017;32(5):377-89.

- 195 13. Lim SY, Bae EH, Han KD, Jung JH, Choi HS, Kim HY, et al. Systemic lupus erythematosus is a risk
- 196 factor for cardiovascular disease: a nationwide, population-based study in Korea. Lupus.
- 197 2018;27(13):2050-6.
- 198 14. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G.
- 199 Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology
- 200 (Oxford). 2014;53(8):1470-6.
- 201 15. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Complications Attributed to
- 202 Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf. 2018;41(10):919-
- 203 31.

204

Table 1. Mendelian randomization (MR) analyses between systemic lupus erythematosus (SLE) and congestive heart failure (CHF).

	Whole SLE-associated SNP on CHF		Non-HLA SLE-associated SNP on CHF			
	OR (95% CI)	P-value	NSNP	OR (95% CI)	P-value	NSNP
IVW	1.032 (1.004–1.061)	0.023	30	1.034 (1.007–1.062)	0.015	27
Weighted median	1.024 (0.985–1.064)	0.233	30	1.024 (0.986–1.063)	0.223	27
Maximum likelihood	1.033 (1.006–1.060)	0.015	30	1.034 (1.007–1.063)	0.013	27
IVW (Radial)	1.032 (1.004–1.061)*	0.023	30	1.034 (1.007–1.062)**	0.015	27
MR-RAPS	1.032 (1.003–1.061)	0.029	30	1.032 (1.004–1.062)	0.024	27
MR Steiger directionality	-	<0.001	30	-	<0.001	27
MR-PRESSO [†]	-	0.451	30	-	0.689	27
MR-Egger intercept [‡]	0.01067 (0.01072)	0.328	30	0.00930 (0.01051)	0.385	27

OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism; NSNP, the number of SNPs;

206

207

208

209

210

211

212

213

214

IVW, inverse-variance weighted method; HLA, human leukocyte antigen.

^{*}The outlying variants (rs143821594 and rs4930642) were detected.

^{**}The outlying variant (rs4930642) was detected.

[†]No outlying pleiotropic variants were detected.

[‡]The Egger intercept value and SE are presented. There was no evidence of significant horizontal pleiotropy.




Figure S1. The leave-one-out sensitivity analysis for the causal association of systemic lupus erythematosus with congestive heart failure using the inverse-variance weighted method. (A) The whole genetic variants associated with SLE were used. (B) The only non-HLA genetic variants were used. SLE, systemic lupus erythematosus; CHF, congestive heart failure; HLA, human leukocyte antigen.




Figure S2. The radial Mendelian randomization plot. Blue and orange dots indicate valid genetic variants and the outliers (rs143821594 and rs4930642), respectively. The estimated effect sizes are presented. (A) The whole genetic variants associated with SLE were used. (B) The only non-HLA genetic variants were used. IVW, inverse-variance weighted method; SLE, systemic lupus erythematosus; CHF, congestive heart failure; HLA, human leukocyte antigen.

Table S1. Genetic instruments for systemic lupus erythematosus in the East Asian population

(P<5x10⁻⁸).

230

231

SNP	Position (GRCh37)	EA/OA	Beta (SE)	P-value
rs201036579	chr1:157499390	C/T	-0.288 (0.053)	4.85E-08
rs4916315	chr1:173215372	T/C	0.336 (0.031)	4.12E-27
rs13385731	chr2:33701890	C/T	-0.365 (0.042)	4.19E-18
rs11889341	chr2:191943742	T/C	0.416 (0.03)	3.33E-45
rs7650774	chr3:119205050	C/T	-0.18 (0.031)	4.07E-09
rs10516487	chr4:102751076	A/G	-0.255 (0.04)	1.64E-10
rs244689	chr5:133422816	G/A	-0.16 (0.029)	4.29E-08
rs10036748	chr5:150458146	T/C	0.202 (0.034)	2.29E-09
rs2431697	chr5:159879978	C/T	-0.254 (0.045)	1.84E-08
rs6941485	chr6:250619	G/A	0.203 (0.031)	9.53E-11
rs2524058*	chr6:31251569	G/A	-0.186 (0.03)	5.31E-10
rs6941112*	chr6:31946614	A/G	0.222 (0.033)	1.01E-11
rs143821594*	chr6:32204017	C/T	-0.495 (0.055)	3.08E-19
rs3734266	chr6:34823187	C/T	0.334 (0.04)	6.09E-17
rs4134466	chr6:106577368	G/A	-0.214 (0.031)	3.09E-12
rs9387400	chr6:116694120	A/C	-0.297 (0.054)	3.14E-08
rs5029937	chr6:138195151	T/G	0.684 (0.068)	4.32E-24
rs76571753	chr7:73974915	T/G	0.279 (0.041)	1.46E-11
rs10953792	chr7:75172937	C/T	0.199 (0.032)	4.69E-10
rs4731532	chr7:128572766	A/G	0.372 (0.033)	8.15E-29
rs2618473	chr8:11344127	T/C	0.359 (0.034)	2.89E-26
rs7097397	chr10:50025396	A/G	-0.239 (0.031)	1.32E-14
rs3750996	chr11:4113200	G/A	-0.204 (0.037)	4.91E-08
rs10896045	chr11:65555524	G/A	-0.173 (0.029)	1.78E-09
rs4930642	chr11:68816370	G/A	-0.234 (0.034)	1.10E-11
rs7486387	chr12:12866911	A/G	-0.189 (0.031)	1.98E-09
rs2841281	chr14:105394669	T/C	0.193 (0.029)	3.56E-11
rs12599402	chr16:11189888	C/T	-0.198 (0.029)	1.02E-11
rs9938016	chr16:86002524	T/C	-0.397 (0.059)	1.78E-11
rs55701306	chr17:16842447	T/C	0.166 (0.029)	1.38E-08

SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; SE, standard error.

^{**}SNPs located in the extended HLA region (chromosome 6: 27–34 Mb).

Table S2. Mendelian randomization (MR) analyses between systemic lupus erythematosus (SLE)

and congestive heart failure (CHF) after excluding the entire chromosome 6.

	OR (95% CI)	P-value	NSNP
IVW	1.037 (1.004–1.072)	0.030	22
Weighted median	1.031 (0.987–1.077)	0.170	22
Maximum likelihood	1.038 (1.007–1.070)	0.017	22
IVW (Radial)*	1.037 (1.004–1.072)	0.030	22
MR-RAPS	1.037 (1.002–1.074)	0.038	22
MR Steiger directionality	-	<0.001	22
MR-PRESSO [†]	-	0.439	22
MR-Egger intercept [‡]	0.01224 (0.01403)	0.393	22

OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism; NSNP, the number of SNPs;

235

236

239

241

242

²³⁸ IVW, inverse-variance weighted method.

^{*}The outlying variant (rs4930642) was detected.

[†]No outlying pleiotropic variants were detected.

[‡]The Egger intercept value and SE are presented. There was no evidence of significant horizontal pleiotropy.